Category: Companion Diagnostics

Gene Analysis BRACAnalysis CDx® BRACAnalysis CDx® – Confidently Recommend an Appropriate PARP Inhibitor with Fast and Accurate BRCA1/2 Results   Germline BRCA1 and BRCA2 status is a critical biomarker to help you determine the appropriate therapy for your patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer. BRACAnalysis CDx® was designed to quickly…

About myCHOICE CDx® Plus myCHOICE CDx® Plus – The most comprehensive HRD tumor test to guide PARP inhibitor treatment decisions. Homologous Recombination Deficiency (HRD) is present in approximately 48% of ovarian cancer tumors1 and is associated with sensitivity to PARPi therapy.2 International guidelines include recommendations for HRD testing for ovarian cancer.2,3…